# Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

> **NCT03515824** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 22 (actual)

## Conditions studied

- Neoplasms
- Colorectal Neoplasms
- Head and Neck Neoplasms

## Interventions

- **BIOLOGICAL:** MK-1697

## Key facts

- **NCT ID:** NCT03515824
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-13
- **Primary completion:** 2020-02-18
- **Final completion:** 2020-02-18
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2021-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03515824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03515824, "Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03515824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*